Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 16404741

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Cancer
Publication date
2006 Feb 15
First author
Rifkin RM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Rifkin RM
      type
      Author
    2. name
      Gregory SA
      type
      Author
    3. name
      Mohrbacher A
      type
      Author
    4. name
      Hussein MA
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Rifkin RM
      type
      Author
    2. name
      Gregory SA
      type
      Author
    3. name
      Mohrbacher A
      type
      Author
    4. name
      Hussein MA
      type
      Author
    bibliography ids
    1. nci-bib-fc5d30ee7578b9e644998f05
    book metadata
    content sha256
    b592519d9243a936a7b1adfb19c7b4e93dd64cd7596e44450966086f4a4f023e
    document type
    citation
    dois
    1. 10.1002/cncr.21662
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:16404741
    immutable id
    pubmed:16404741@b592519d9243a936a7b1adfb19c7b4e93dd64cd7596e44450966086f4a4f023e
    journal
    abbreviation
    Cancer
    issn electronic
    Source null
    issn print
    0008-543X
    issue
    4
    name
    Cancer
    nlm unique id
    0374236
    pages
    848-58
    volume
    106
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      16404741
      provenance
      batch id
      a181c30258a88d182e78
      provider
      NCBI PubMed ESummary
      record sha256
      ca620b375cba2db093f5a4a21b2a3527ea9a1a2b4fbf6cbcd5938d05ba9fc235
      response sha256
      558e0dce453ae424567844b062522ebd1d27363c3312c81dbf6f32a8ff08da24
      retrieved at
      2026-09-09T23:46:03.896343+00:00
      publication date
      display
      2006 Feb 15
      precision
      day
      year
      2006
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/16404741/
      title
      Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.

      Preserved source evidence · Not medical advice